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Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the 
impact on quality of life: a narrative systematic review.
Objective: To identify any change in quality of life (QoL) caused by 
chemotherapy-induced toxicities, such as hearing loss and tinnitus, to provide 
information in order to improve services and aid clinicians in their decision-
making. 
Design: This systematic review followed the PRISMA checklist. The search 
terms were cancer, platinum-based chemotherapy, ototoxicity and “quality of 
life”. Titles and abstracts, followed by full texts, were screened by two 
independent researchers. The relevant data were extracted and quality analysis 
was performed using the NIH Quality Assessment Tool. 
Study Sample: 308 titles and abstracts were screened, and 27 full text articles 
were screened. Ten articles representing 11 studies were included in the review. 
Study design included cross-sectional studies, randomised control trials and 
longitudinal studies. 
Results: Diagnostic criteria consisted of audiograms, questionnaires, and patient 
complaints. The study quality ranged from 21.43% to 85.71%. Overall results 
found that those treated with cisplatin had more hearing loss and tinnitus than 
those treated with other therapies. Furthermore, those with hearing loss and 
tinnitus were more likely to have a lower QoL.
Conclusions: There is an urgent need to standardise diagnostics when 
investigating ototoxicity and its effect on QoL, particularly for research into risk 
factors, prevention and management. 
Keywords: cancer, platinum-based chemotherapy, survivorship, ototoxicity, 
hearing, tinnitus, quality of life
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Introduction
Cancer continues to be a life-altering diagnosis, however due to medical advances there has 
been an overall decline of 26% in cancer deaths within the past two decades (Siegel, Miller, 
and Jemal 2018). Treatment effects, though, can often cause long-term physical and 
psychological challenges for survivors (Skalleberg et al. 2017; Alfano and Rowland 2006). 
For this reason, there is a requirementto look into how these long-term effects impact  (QoL) 
for those who are adapting to a life with and beyond cancer. 
Platinum-based chemotherapy is typically used to treat most solid tumours, including 
breast, testicular and ovarian cancers (Oun, Moussa, and Wheate 2018; Theile and Dirk 2017; 
Kelland 2007). Due to its cost effective systematic and cytotoxic effects, it has been one of 
the most efficient and widely available chemotherapies (Paken et al. 2016). However, it is 
widely known that platinum-based chemotherapycan cause ototoxicity (Campbell and Le 
Prell 2018; Saladin et al. 2015). Ototoxicity refers to any hearing deficit or tinnitus resulting 
from a temporary or permanent inner ear dysfunction, following treatment with an ototoxic 
drug (Paken et al. 2016). Ototoxic drugs include aminoglycoside antibiotics such as 
gentamicin, loop diuretics such as torasemide and neurologic drugs, such as sodium valproate 
(Bisht and Bist 2011). Ototoxic effects commonly manifest as tinnitus and/or high frequency 
hearing loss that can later progress to lower frequencies (Waissbluth, Peleva, and Daniel 
2017). Both tinnitus and hearing loss are associated with a higher risk of depression, social 
isolation, anxiety (Nordvik et al. 2018) and dementia (Gurgel et al. 2014; Deal et al. 2016).
It may not be possible to identify the specific time point during treatment at which an 
effect first appears, making it challenging to determine the causality and risk of each therapy 
received (Stein, Syrjala, and Andrykowski 2008). For this reason, literature reporting adverse 
health effects associated with chemotherapy can be imprecise and lacking in detail.
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Furthermore, collating systematic evidence on adverse effects can be difficult. 
Specific toxicities are rarely included in key words, titles or abstracts. To overcome this 
challenge, a compromise between sensitivity and precision must be made when performing a 
systematic search (Golder and Loke 2009).
To date, there have been no systematic reviews carried out exploring the impact on 
QoL from platinum-based chemotherapy-induced ototoxicity. 
Materials and Meth ds
Eligibility Criteria
The four themes that had to be present in an article were: any mention of cancer, platinum-
based chemotherapy, ototoxicity and QoL. Known key articles were checked in the searches 
to ensure all relevant articles were included in the search. There was no limitation on the date 
range of this search.
The inclusion criteria consisted of: any combination of treatments which included 
platinum-based chemotherapy for curative intent, any type of formal QoL assessment, any 
type of formal hearing loss and/or tinnitus assessment, written in the English language, any 
study design providing the relevant results were obtained after treatment and any cancer type 
other than head and neck. Any paediatric study was excluded, in addition to review articles, 
grey literature and both in vitro and in vivo studies. 
Information Sources
This systematic review was conducted following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) checklist.
Due to the nature of this systematic review and the difficulties in searching for 
adverse effects of chemotherapy, specificity and precision were optimised in order to capture 
the most relevant articles and reduce unrelated articles. The terms used were edited 
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accordingly to meet the standards of each search engine.
Search engines used were OVIDSP, NCBI, WebofScience and Cochrane. Databases 
searched therefore consisted of Medline, Pyschinfo and PyschArticles, Embase, PubMed, 
WebofScience Core Collection and the Cochrane Database. 
Study Selection 
Titles and abstracts were imported to Endnote, duplicates were removed and the remainder 
were screened by two independent authors (SP and JT) against the eligibility criteria. Any 
disagreement was resolved by consensus. Full-text articles of potentially relevant papers were 
also assessed for eligibility,  resolving any discrepancies by consensus. 
Data Extraction Process
Determinants such as paper characteristics, type of study design, sample size, patient 
demographics, and the measurements used and analysed, in addition to the results of the 
specific study, were all extracted. The information that could be compared across studies was 
then analysed accordingly, with the remaining information displayed as a description in order 
to capture the full results. 
Risk of Bias in Individual Studies
A quality assessment was carried out on each of the studies included in this review using a 
14-item study quality assessment tool involving pre-defined principles, the NIH’s Quality 
Assessment Tools (“Study Quality Assessment Tools | National Heart, Lung, and Blood 
Institute (NHLBI)” 2018). An item was scored 1 for matching the criteria, and scored 0 if it 
was not clear or did not match the criteria. Aggregate percentages were used to classify poor-
quality (≤50%), and high-quality (>50%) studies. This tool was chosen based on a systematic 
review carried out by Mols, et.al  (Mols et al. 2015). The tool was chosen as it assessed 
relevant aspects for each study type involved in this review. The-high quality and low-quality 
studies were grouped, and their results were compared to evaluate consistencies and 
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anomalies.  
Synthesis of Results
Due to the heterogeneity of the results reported in this review, it was not possible to 
statistically combine the results. Therefore, a narrative analysis was carried out, and these 
descriptive results of each study were compared with one another. 
Outcome measures from the studies were extracted and compared, including the 
diagnostic criteria and grading systems used. 
Risk of Bias Across Studies
The majority of the adverse effects within the studies were not clearly defined, therefore the 
risk of bias between studies was relatively high. Moreover, not all diagnostic criteria were 
specified, meaning some studies reported presence of ototoxicity but did not clarify its 
severity or symptom characteristics, i.e. whether it was hearing loss or tinnitus. The non-
randomised studies were also considered to carry a high risk of bias, as trials without blinding 
are prone to bias (Loke, Price, and Herxheimer 2007).
Results
Study Selection
A total of 645 articles were identified through the database searches performed. From this, 
337 articles were excluded due to duplications, grey literature and there being no abstracts 
available. The resulting 308 titles and abstracts were screened. The screening procedure can 
be seen inin Figure 1.
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Figure 1 displaying the PRISMA flowchart methodology and results obtained for this 
systematic review.
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Study Characteristics 
The following study characteristics were extracted, as shown in Table 1: location of study, 
type of study design, population characteristics, number of participants, number of 
participants treated with platinum-based chemotherapy, diagnostic measurements for 
ototoxicity, hearing loss, tinnitus and QoL, type of platinum-based chemotherapy, follow-up 
period, main objective of study and a descriptive summary of the study. 
 There were six cross-sectional studies included in this systematic review, each with 
variable timeframes since diagnosis (Bentzen et al. 2013; Bokemeyer et al. 1996; Calhoun et 
al. 1998; Miaskowski, Paul, Mastick, Schumacher, et al. 2018; Miaskowski, Paul, Mastick, 
Abrams, et al. 2018; Miaskowski, Mastick, Paul, Abrams, et al. 2018b). In total, 856 
participants were included; 565 of these received platinum-based chemotherapy. Two 
randomised control trials compared cisplatin-based regimens with other types of treatments 
and included 553 patients, with 313 of these having a platinum-based treatment (Bezjak et al. 
2008; Saad, Ghali, and Shawki 2017). Only one longitudinal study was included in this 
systematic review, following 666 patients with metastatic testicular cancer on two different 
cisplatin regimens, with 286 (52%) being followed up at 2 years (Fosså et al. 2003). Finally, 
one paper involved two separate pilot studies on low-stage testicular cancer survivors from 
Norway and the UK (Fossa and Fossg 1996). This study involved comparing opinions on 
toxicities of those treated with infradiaphragmatic radiotherapy, cisplatin, or surveillance and 
the opinions of a variety of healthcare professionals. From the 309 participants involved, 71 
of these received cisplatin. 
Most did not report the demographics within each comparison group, but as a whole. 
For example, the Bentzen, et al. paper describes patient characteristics as 79% women and 
21% men, with a median age of 61, and a range of 40-89 years old for survivors who 
responded to the survey (Bentzen et al. 2013). Although the information contains those 
Page 9 of 58
E-mail:editor.ija@up.ac.za  URL: http://mc.manuscriptcentral.com/tija
International Journal of Audiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
8
treated with cisplatin (n= 56), it is not possible to isolate the gender split and age range of this 
exact subgroup. 
Eight of the studies included cisplatin as the platinum-based chemotherapy, and three 
of the studies carried out by Miaskowskind colleagues do not specify which platinum-based 
chemotherapy was used (Miaskowski, Paul, Mastick, Abrams, et al. 2018; Miaskowski, 
Mastick, Paul, Abrams, et al. 2018a; Miaskowski, Paul, Mastick, Schumacher, et al. 2018). 
Only one study investigated the difference between carboplatin and cisplatin (Saad, Ghali, 
and Shawki 2017). Moreover, only one study compared the toxicities with those treated with 
cisplatin to the normal population (Bentzen et al. 2013). 
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Table 1 displays the study characteristics extracted for this review, including the author, type 
of study, cancer type, type of platinum-based chemotherapy used, number of participants 
involved and number of participants involved treated with platinum-based chemotherapy
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Risk of Bias 
The NIH Quality Assessment Tool (“Study Quality Assessment Tools | National Heart, Lung, 
and Blood Institute (NHLBI)” 2018) was used to assess each of the individual studies. The 
appraisal criteria involved answering 14 binary questions on the quality of the article. Table 2 
displays the quality score for each assessment and the quality percentage calculated, with 
green being a good-quality study and red being a poor-quality study. Those with a score of 
>50% (n=7) were classed as a high-quality study, and those ≤50% (n=4) were classed as a 
poor-quality study. The studies were grouped according to quality to compare any differences 
in results and identify any contradicting information. 
The papers with a quality score ≤50% (n=4) all compared opinions of patients and 
healthcare professionals. The papers concluded that most patients perceived the effects of  
ototoxicity as tolerable, whereas those in health professions perceived the toxicity to affect 
QoL. However, these studies were all based on hypothetical scenarios and not real life 
experiences, therefore it could be hypothesised that patients may not realise the extent to 
which QoL can change when experiencing ototoxicity, compared to professionals. All but 
one study scoring >50% concluded that QoL is indeed affected by tinnitus and/or hearing 
loss, adding that severity correlated with the dosage and number of cycles. However, one 
high quality study carried out by Bezjack, et.al. 2008 found no difference in the QoL assessed 
across different treatments, regardless of experiencing ototoxicity. Yet, this study found that 
ototoxicity did indeed persist beyond treatment (Bezjak et al. 2008). There were no 
significant differences in results from the high quality studies compared to the lower quality 
studies. 
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Table 2 displays the study and the critical appraisal score for each study, using the NIH 
Quality Assessment Tool.
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Results of the Individual Studies
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The data extracted in 
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Table 3 demonstrates that there is no standardised outcome measurement used to assess 
ototoxicity. For example, many of the measurements used in the study analysed ototoxicity, 
yet did not specify or define ototoxicity. These studies could have measured either hearing 
loss or tinnitus. Furthermore, many studies did not consider the severity or grading of 
ototoxicity. One study did, however, perform pure tone audiometry with bone conduction 
thresholds on patients to assess the extent of their hearing loss (Bokemeyer et al. 1998). 
The studies carried out by Miaskowski assessed 8 aspects of QoL in addition to a 
questionnaire identifying the severity of hearing loss and the severity of tinnitus as separate 
items. Tinnitus was defined as “ringing or buzzing in the ears” (Miaskowski, Paul, Mastick, 
Schumacher, et al. 2018; Miaskowski, Mastick, Paul, Abrams, et al. 2018a; Miaskowski, 
Paul, Mastick, Abrams, et al. 2018). The studies compared those with hearing loss, tinnitus 
and neuropathy to those with just one of the toxicities and those with no toxicities. However, 
these studies do not report which platinum-based chemotherapy was used, the regimen used, 
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the dosage or how many cycles each patient received. 
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Table 3 displays the results extracted from the individual studies in the systematic review. 
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Table 3 continued. 
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Discussion
Overall, the results found that those treated with platinum-based chemotherapy, specifically 
cisplatin, had significantly more hearing loss and tinnitus than the comparisonpopulation, 
with higher doses correlating to persisting symptoms. These results are corroborated by the 
wider literature, as it is reported that on average, 60-70% of adult patients experienced 
ototoxicity when treated with cisplatin (Chirtes and Albu 2016; Campbell and Le Prell 2018; 
Frisina et al. 2016; Travis et al. 2014). Tinnitus has also been reported in previous studies, 
particularly those with high doses of cisplatin (Campbell and Le Prell 2018). This review 
found that those with tinnitus and hearing loss were more likely to have a lower QoL. 
It is common for there to be a reduction in QoL following the first three cycles of 
platinum-based chemotherapy in adults (Kalyanam et al. 2018). Furthermore, it is well 
documented that hearing loss negatively impacts mental wellbeing and QoL, although the use 
of hearing aids appear to improve general QoL within the first year, emphasising the 
importance of early and proper diagnosis (Hogan et al. 2015; Fellinger et al. 2007). Tinnitus 
has also been shown to be a significant burden on QoL and has a strong association with 
depression in the general population (Zeman et al. 2014; Nondahl et al. 2007). From this, it 
can be inferred that ototoxicity in cancer survivors can directly cause a reduction in QoL. 
However, due to the heterogeneity of the study designs and the lack of research carried out in 
this field, it cannot be categorically stated that this is true. 
The studies included in this review were highly variable in both their methodology 
and results. The results clearly highlight the lack of standardisation in reporting QoL and 
ototoxicity diagnostics. Furthermore, the lack of grading means that individuals could be 
suffering from ototoxic effects and it not be reported adequately in study settings, or the 
opposite, where the reporting overestimates the ototoxic effect. Therefore, it is difficult to 
assess the strength of the results as a whole, as the nature of this field is heterogeneous. The 
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lack of standardised diagnostic and grading systems is the most significant weakness in the 
reviewed studies. By pooling together similar data and carrying out a meta-analysis, powerful 
information could be identified and published, which in turn will help inform and develop 
better care and management for those experiencing ototoxicity. This research has typically 
consisted of a multitude of small-scale studies looking into different factors, making it 
difficult to compare information statistically. However, the information and data regarding 
genetic susceptibilities of ototoxicity have been statistically systematically analysed. Studies 
of high-quality and large population sizes have found that between 29-40% of testicular 
cancer patients have an ototoxic phenotype (Wheeler et al. 2015). Furthermore, a meta-
analysis of phenotypes have found a multitude of genes, including those that play a role in 
calcium homeostasis and are associated with an increased risk of ototoxicity (Tserga et al. 
2019).
Audiometry is a standardised and widely available method for quantifying hearing 
status. There are also a variety of validated tinnitus questionnaires that are used clinically for 
diagnosing and quantifying tinnitus severity readily available. Ideally, it should be clinical 
practise that in the event a patient presents with ototoxicity that these assessments be carried 
out. However, because chemotherapy is associated with many acute and life-threatening side 
effects, it is unrealistic and time-consuming to have measurement tools for each individual 
and specific side effect. However, it is of high clinical importance for the dose-limiting or 
permanent side effects to be identified and managed. For this reason, questionnaires such as 
the Scale for chemotherapy-induced long-term neurotoxicity (SCIN) which group together 
the neurotoxic side effects, are well-used outcome measures (Oldenburg et al. 2006). These 
type of assessments, although more time-efficient, lack collecting valid information. For 
example, the questions are vague and do not allow clinicians to differentiate one toxicity 
from another, meaning the management and support offered isn’t useful. Another example of 
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this is the Holistic Needs Assessment (HNA), which asks if “you have had any change in 
sight or hearing” (Wells, Semple, and Lane 2015; Biddle et al. 2016). This, although helpful 
in developing a tailored care plan, does not identify specific side effects, the severity of them 
or if it affects QoL. Furthermore, by identifying a change in hearing and/or sight, it is unclear 
which specialist the patients should be referred to, an optician or an audiologist? Therefore, 
the balance between not overwhelming a patient, yet also collecting reliable and detailed 
information about their side effects appears a seemingly impossible challenge. This has been 
highlighted regularly in literature, with many new proposals on which diagnostic criteria 
should be used to identify the presence and severity of ototoxicity, yet no standardised 
measures are implemented clinically at the present time (Theunissen et al. 2014; Chang 2011; 
Waissbluth, Peleva, and Daniel 2017; Crundwell, Gomersall, and Baguley 2016; Degeest et 
al. 2016).
There are many potential confounding factors when assessing ototoxicity and how it 
impacts quality of life, including age at treatment, number of follow-ups and the timing of 
these follow-ups, type of treatment, dosage of treatment, type of quality of life assessment 
and the setting these were carried out in. Furthermore, the language used in the assessment 
tools can also lead to patients providing unreliable and confusing information, which does not 
always reflect their true experience. The readability of the questionnaires, therefore, is also an 
important confounding factor that should be considered when analysing this type of 
information (Atcherson et al. 2013; Gray, Zraick, and Atcherson 2019; Douglas and Kelly-
Campbell 2018). 
The term “ototoxicity” must be defined when publishing trials and research studies. 
There needs to be a clear definition of what the authors mean, and differentiation between 
hearing loss and tinnitus information (Waissbluth, Peleva, and Daniel 2017). Without this, a 
detailed analysis on the severity and effect on QoL remains a challenge.  
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Finally, although survival rates remain the priority in cancer treatment, there needs to 
be more emphasis on the importance of permanent toxicities. As people survive longer and it 
becomes clear that there will be a life beyond cancer, QoL becomes increasingly important. 
More awareness of how long-term toxicities, such as hearing loss and tinnitus, can affect 
QoL, needs to be integrated into clinical practice. By raising awareness, the risk of these 
issues being neglected will decrease. Patients guided through the survivorship journey can be 
given relevant and tailored support, be it hearing aids, tinnitus sound therapy or cognitive 
behavioural therapy (CBT). Ototoxicity is currently neither preventable nor curable, therefore 
it is essential that a deeper understanding and increased awareness of how hearing loss and 
tinnitus affects the QoL of cancer survivors be established in order to improve long-term 
symptom management.
Acknowledgements
This report is independent research by the National Institute for Health Research 
Biomedical Research Centre Funding Scheme. The views expressed in this publication are 
those of the author(s) and not necessarily those of the NHS, the National Institute for Health 
Research or the Department of Health.
Declaration of Interest Statement
None declared.
References
Alfano, Catherine M, and Julia Rowland. 2006. “Recovery Issues in Cancer Survivorship: A 
New Challenge for Supportive Care.” The Cancer Journal 12 (5): 432–443. 
https://journals.lww.com/journalppo/Abstract/2006/09000/Recovery_Issues_in_Cancer_
Survivorship__A_New.12.aspx.
Atcherson, Samuel R., Cynthia M. Richburg, Richard I. Zraick, and Cassandra M. George. 
2013. “Readability of Questionnaires Assessing Listening Difficulties Associated With 
(Central) Auditory Processing Disorders.” Language, Speech, and Hearing Services in 
Schools 44 (1): 48–60. doi:10.1044/0161-1461(2012/11-0055).
Bentzen, Anne Gry, Lise Balteskard, Eva Hoff Wanderås, Gunilla Frykholm, Tom 
Wilsgaard, Olav Dahl, Marianne Grønlie Guren, et al. 2013. “Impaired Health-Related 
Page 23 of 58
E-mail:editor.ija@up.ac.za  URL: http://mc.manuscriptcentral.com/tija
International Journal of Audiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
22
Quality of Life after Chemoradiotherapy for Anal Cancer : Late Effects in a National 
Cohort of 128 Survivors Impaired Health-Related Quality of Life after 
Chemoradiotherapy for Anal Cancer : Late Effects in a National Cohort of 128.” 
doi:10.3109/0284186X.2013.770599.
Bezjak, Andrea, Christopher W Lee, Keyue Ding, Michael Brundage, Timothy Winton, 
Barbara Graham, Marlo Whitehead, et al. 2008. “Quality of Life Outcomes for Adjuvant 
Chemotherapy in Early-Stage Non – Small-Cell Lung Cancer : Results From a 
Randomized Trial, JBR.10.” Journal of Clinical Oncology 26 (31). 
doi:10.1200/JCO.2007.12.6094.
Biddle, Lucy, Sangeetha Paramasivan, Susan Harris, Rona Campbell, James Brennan, and 
William Hollingworth. 2016. “Patients’ and Clinicians’ Experiences of Holistic Needs 
Assessment Using a Cancer Distress Thermometer and Problem List: A Qualitative 
Study.” European Journal of Oncology Nursing 23 (August). Churchill Livingstone: 
59–65. doi:10.1016/J.EJON.2016.04.004.
Bisht, Manisha, and S. S. Bist. 2011. “Ototoxicity: The Hidden Menace.” Indian Journal of 
Otolaryngology and Head & Neck Surgery 63 (3). Springer-Verlag: 255–259. 
doi:10.1007/s12070-011-0151-8.
Bokemeyer, C, C C Berger, J T Hartmann, C Kollmannsberger, H J Schmoll, M A Kuczyk, 
and L Kanz. 1998. “Analysis of Risk Factors for Cisplatin-Induced Ototoxicity in 
Patients with Testicular Cancer.” British Journal of Cancer 77 (8). Nature Publishing 
Group: 1355–1362. http://www.ncbi.nlm.nih.gov/pubmed/9579846.
Bokemeyer, C, C C Berger, M A Kuczyk, and H J Schmoll. 1996. “Evaluation of Long-Term 
Toxicity after Chemotherapy for Testicular Cancer.” Journal of Clinical Oncology 14 
(11): 2923–2932. doi:10.1200/JCO.1996.14.11.2923.
Calhoun, Elizabeth A, D Ph, Charles L Bennett, D Ph, Patti A Peeples, D Ph, John R Lurain, 
Philip Y Roland, Jill M Weinstein, and David A Fishman. 1998. “Perceptions of 
Cisplatin-Related Toxicity among Ovarian Cancer Patients and Gynecologic 
Oncologists” 375: 369–375.
Campbell, Kathleen C. M., and Colleen G. Le Prell. 2018. “Drug-Induced Ototoxicity: 
Diagnosis and Monitoring.” Drug Safety 41 (5): 451–464. doi:10.1007/s40264-017-
0629-8.
Chang, Kay W. 2011. “Clinically Accurate Assessment and Grading of Ototoxicity.” 
Laryngoscope 121 (12): 2649–2657. doi:10.1002/lary.22376.
Chirtes, Felician, and Silviu Albu. 2016. “Prevention and Restoration of Hearing Loss 
Associated with the Use of Cisplatin.” BioMed Research International 2014 (July 2014). 
doi:10.1155/2014/925485.
Crundwell, Gemma, Phil Gomersall, and David M. Baguley. 2016. “Ototoxicity 
(Cochleotoxicity) Classifications: A Review.” International Journal of Audiology 55 
(2): 65–74. doi:10.3109/14992027.2015.1094188.
Deal, Jennifer A., Josh Betz, Kristine Yaffe, Tamara Harris, Elizabeth Purchase-Helzner, 
Suzanne Satterfield, Sheila Pratt, et al. 2016. “Hearing Impairment and Incident 
Dementia and Cognitive Decline in Older Adults: The Health ABC Study.” The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 72 (5): 
glw069. doi:10.1093/gerona/glw069.
Page 24 of 58
E-mail:editor.ija@up.ac.za  URL: http://mc.manuscriptcentral.com/tija
International Journal of Audiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
23
Degeest, S, P Corthals, I Dhooge, and H Keppler. 2016. “The Impact of Tinnitus 
Characteristics and Associated Variables on Tinnitus-Related Handicap.” The Journal of 
Laryngology & Otology 130 (01). Cambridge University Press: 25–31. 
doi:10.1017/S0022215115002716.
Douglas, Alana, and Rebecca J. Kelly-Campbell. 2018. “Readability of Patient-Reported 
Outcome Measures in Adult Audiologic Rehabilitation.” American Journal of Audiology 
27 (2): 208–218. doi:10.1044/2018_AJA-17-0095.
Fellinger, J., D. Holzinger, J. Gerich, and D. Goldberg. 2007. “Mental Distress and Quality of 
Life in the Hard of Hearing.” Acta Psychiatrica Scandinavica 115 (3): 243–245. 
doi:10.1111/j.1600-0447.2006.00976.x.
Fosså, By Sophie D, Ronald De Wit, J Trevor Roberts, Peter M Wilkinson, Pieter H M De 
Mulder, Graham M Mead, Pat Cook, et al. 2003. “Quality of Life in Good Prognosis 
Patients With Metastatic Germ Cell Cancer : A Prospective Study of the European 
Organization for Research and Treatment of Cancer Cancer Study Group ( 30941 / TE20 
)” 21 (6): 1107–1118. doi:10.1200/JCO.2003.02.075.
Fossa, Sophie D, and S D Fossg. 1996. “Patients ’ and Doctors ’ Perception of Long-Term 
Morbidity in Patients with Testicular Cancer Clinical Stage I A Descriptive Pilot Study.” 
Supportive Care in Cancer 4 (2): 118–128.
Frisina, Robert D, Heather E Wheeler, Sophie D Fossa, Sarah L Kerns, Chunkit Fung, 
Howard D Sesso, Patrick O Monahan, et al. 2016. “Comprehensive Audiometric 
Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in 
Survivors of Adult-Onset Cancer.” Journal of Clinical Oncology : Official Journal of 
the American Society of Clinical Oncology 34 (23). American Society of Clinical 
Oncology: 2712–2720. doi:10.1200/JCO.2016.66.8822.
Golder, Su, and Yoon Loke. 2009. “Search Strategies to Identify Information on Adverse 
Effects: A Systematic Review.” Journal of the Medical Library Association : JMLA 97 
(2): 84–92. doi:10.3163/1536-5050.97.2.004.
Gray, Sara A., Richard I. Zraick, and Samuel R. Atcherson. 2019. “Readability of Individuals 
With Disabilities Education Act Part B Procedural Safeguards: An Update.” Language, 
Speech, and Hearing Services in Schools, April, 1–12. doi:10.1044/2018_LSHSS-18-
0057.
Gurgel, Richard Klaus, Preston Daniel Ward, Sarah Schwartz, Maria C Norton, Norman L 
Foster, and JoAnn T Tschanz. 2014. “Relationship of Hearing Loss and Dementia: A 
Prospective, Population-Based Study.” Otology & Neurotology : Official Publication of 
the American Otological Society, American Neurotology Society [and] European 
Academy of Otology and Neurotology 35 (5). NIH Public Access: 775–781. 
doi:10.1097/MAO.0000000000000313.
Hogan, Anthony, Rebecca L. Phillips, Susan A. Brumby, Warwick Williams, and Catherine 
Mercer-Grant. 2015. “Higher Social Distress and Lower Psycho-Social Wellbeing: 
Examining the Coping Capacity and Health of People with Hearing Impairment.” 
Disability and Rehabilitation 37 (22): 2070–2075. doi:10.3109/09638288.2014.996675.
Kalyanam, Balamurali, N Sarala, S M Azeem Mohiyuddin, and Ravi Diwakar. 2018. 
“Auditory Function and Quality of Life in Patients Receiving Cisplatin Chemotherapy in 
Head and Neck Cancer: A Case Series Follow-up Study.” Journal of Cancer Research 
Page 25 of 58
E-mail:editor.ija@up.ac.za  URL: http://mc.manuscriptcentral.com/tija
International Journal of Audiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
24
and Therapeutics 14 (5). Medknow Publications and Media Pvt. Ltd.: 1099–1104. 
doi:10.4103/0973-1482.188426.
Kelland, Lloyd. 2007. “The Resurgence of Platinum-Based Cancer Chemotherapy.” Nature 
Reviews Cancer 7 (8): 573–584. doi:10.1038/nrc2167.
Loke, Yoon K, Deirdre Price, and Andrew Herxheimer. 2007. “Systematic Reviews of 
Adverse Effects: Framework for a Structured Approach.” BMC Medical Research 
Methodology 7 (1): 32. doi:10.1186/1471-2288-7-32.
Miaskowski, Christine, Judy Mastick, Steven M. Paul, Gary Abrams, Steven Cheung, 
Jennifer Henderson Sabes, Kord M. Kober, et al. 2018a. “Impact of Chemotherapy-
Induced Neurotoxicities on Adult Cancer Survivors ’ Symptom Burden and Quality of 
Life.” Journal of Cancer Survivorship, November. Journal of Cancer Survivorship, 234–
245. doi:10.1007/s11764-017-0662-8.
Miaskowski, Christine, Judy Mastick, Steven M Paul, Gary Abrams, Steven Cheung, Jennifer 
Henderson Sabes, Kord M Kober, et al. 2018b. “Impact of Chemotherapy-Induced 
Neurotoxicities on Adult Cancer Survivors ’ Symptom Burden and Quality of Life.” 
Journal of Cancer Survivorship, 234–245.
Miaskowski, Christine, Steven M. Paul, Judy Mastick, Mark Schumacher, Yvette P. Conley, 
Betty Smoot, Gary Abrams, et al. 2018. “Hearing Loss and Tinnitus in Survivors with 
Chemotherapy-Induced Neuropathy.” European Journal of Oncology Nursing 32 (July 
2017). Elsevier: 1–11. doi:10.1016/j.ejon.2017.10.006.
Miaskowski, Christine, Steven M Paul, Judy Mastick, Gary Abrams, Kimberly Topp, Betty 
Smoot, Kord M Kober, et al. 2018. “Associations Between Perceived Stress and 
Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer 
Survivors.” Journal of Pain and Symptom Management. Elsevier Inc. 
doi:10.1016/j.jpainsymman.2018.02.021.
Mols, Floortje, Ad J.J.M. Vingerhoets, Jan Willem Coebergh, and Lonneke V. van de Poll-
Franse. 2005. “Quality of Life among Long-Term Breast Cancer Survivors: A 
Systematic Review.” European Journal of Cancer 41 (17). Pergamon: 2613–2619. 
doi:10.1016/J.EJCA.2005.05.017.
Nondahl, David M., Karen J. Cruickshanks, Dayna S. Dalton, Barbara E.K. Klein, Ronald 
Klein, Carla R. Schubert, Ted S. Tweed, and Terry L. Wiley. 2007. “The Impact of 
Tinnitus on Quality of Life in Older Adults.” Journal of the American Academy of 
Audiology 18 (3): 257–266. doi:10.3766/jaaa.18.3.7.
Nordvik, Øyvind, Peder O. Laugen Heggdal, Jonas Brännström, Flemming Vassbotn, Anne 
Kari Aarstad, and Hans Jørgen Aarstad. 2018. “Generic Quality of Life in Persons with 
Hearing Loss: A Systematic Literature Review.” BMC Ear, Nose and Throat Disorders 
18 (1). BioMed Central: 1. doi:10.1186/s12901-018-0051-6.
Oldenburg, Jan, Sophie D Fossa, Alv A. Dahl, Sophie D. Fosså, and Alv A. Dahl. 2006. 
“Scale for Chemotherapy-Induced Long-Term Neurotoxicity (SCIN): Psychometrics, 
Validation, and Findings in a Large Sample of Testicular Cancer Survivors.” Quality of 
Life Research 15 (5): 791–800. doi:10.1007/s11136-005-5370-6.
Oun, Rabbab, Yvonne E. Moussa, and Nial J. Wheate. 2018. “The Side Effects of Platinum-
Based Chemotherapy Drugs: A Review for Chemists.” Dalton Transactions 47 (19). 
The Royal Society of Chemistry: 6645–6653. doi:10.1039/C8DT00838H.
Page 26 of 58
E-mail:editor.ija@up.ac.za  URL: http://mc.manuscriptcentral.com/tija
International Journal of Audiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
25
Paken, Jessica, Cyril D. Govender, Mershen Pillay, and Vikash Sewram. 2016. “Cisplatin-
Associated Ototoxicity: A Review for the Health Professional.” Journal of Toxicology 
2016. doi:10.1155/2016/1809394.
Saad, Amr Shafik, Ramy R Ghali, and May Ahmed Shawki. 2017. “A Prospective 
Randomized Controlled Study of Cisplatin versus Carboplatin-Based Regimen in 
Advanced Squamous Nonsmall Cell Lung Cancer.” Journal of Cancer Research and 
Therapeutics 13 (2). Medknow Publications and Media Pvt. Ltd.: 198–203. 
doi:10.4103/0973-1482.187287.
Saladin, Shawn P, Robert B Perez, Bianca Cruz PharmD, Yasar Tasnif PharmD, CPM B 
Robert Perez Bianca Cruz, and PharmD Yasar Tasnif. 2015. “A Review of Ototoxic 
Medications: Implications for Professionals Working with Consumers with Hearing 
Loss.” Journal of the American Deafness and Rehabilitation Association 49. 
http://repository.wcsu.edu/jadara.
Siegel, Rebecca L., Kimberly D. Miller, and Ahmedin Jemal. 2018. “Cancer Statistics, 
2018.” CA: A Cancer Journal for Clinicians 68 (1): 7–30. doi:10.3322/caac.21442.
Skalleberg, Jakob, Olesya Solheim, Sophie D. Fosså, Milada Cvancarova Småstuen, Terje 
Osnes, Per Ole M. Gundersen, and Marie Bunne. 2017. “Long-Term Ototoxicity in 
Women after Cisplatin Treatment for Ovarian Germ Cell Cancer.” Gynecologic 
Oncology 145 (1). Elsevier Inc.: 148–153. doi:10.1016/j.ygyno.2017.02.006.
Stein, Kevin D., Karen L. Syrjala, and Michael A. Andrykowski. 2008. “Physical and 
Psychological Long-Term and Late Effects of Cancer.” Cancer 112 (S11). Wiley-
Blackwell: 2577–2592. doi:10.1002/cncr.23448.
“Study Quality Assessment Tools | National Heart, Lung, and Blood Institute (NHLBI).” 
2018. Accessed November 1. https://www.nhlbi.nih.gov/health-topics/study-quality-
assessment-tools.
Theile, Dirk, and Dirk. 2017. “Under-Reported Aspects of Platinum Drug Pharmacology.” 
Molecules 22 (3). Multidisciplinary Digital Publishing Institute: 382. 
doi:10.3390/molecules22030382.
Theunissen, Eleonoor A R, Wouter A. Dreschler, Merel N. Latenstein, Coen R N Rasch, 
Sieberen Van Der Baan, Jan Paul De Boer, Alfons J M Balm, and Charlotte L. Zuur. 
2014. “A New Grading System for Ototoxicity in Adults.” Annals of Otology, Rhinology 
and Laryngology 123 (10): 711–718. doi:10.1177/0003489414534010.
Travis, Lois B., Sophie D. Fossa, Howard D. Sesso, Robert D. Frisina, David N. Herrmann, 
Clair J. Beard, Darren R. Feldman, et al. 2014. “Chemotherapy-Induced Peripheral 
Neurotoxicity and Ototoxicity: New Paradigms for Translational Genomics.” Journal of 
the National Cancer Institute 106 (5). doi:10.1093/jnci/dju044.
Tserga, Evangelia, Tara Nandwani, Niklas K. Edvall, Jan Bulla, Poulam Patel, Barbara 
Canlon, Christopher R. Cederroth, and David M. Baguley. 2019. “The Genetic 
Vulnerability to Cisplatin Ototoxicity: A Systematic Review.” Scientific Reports 9 (1). 
Nature Publishing Group: 3455. doi:10.1038/s41598-019-40138-z.
Waissbluth, Sofia, Emilia Peleva, and Sam J. Daniel. 2017. “Platinum-Induced Ototoxicity: 
A Review of Prevailing Ototoxicity Criteria.” European Archives of Oto-Rhino-
Laryngology 274 (3). Springer Berlin Heidelberg: 1187–1196. doi:10.1007/s00405-016-
4117-z.
Page 27 of 58
E-mail:editor.ija@up.ac.za  URL: http://mc.manuscriptcentral.com/tija
International Journal of Audiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
26
Wells, M., C.J. Semple, and C. Lane. 2015. “A National Survey of Healthcare Professionals’ 
Views on Models of Follow-up, Holistic Needs Assessment and Survivorship Care for 
Patients with Head and Neck Cancer.” European Journal of Cancer Care 24 (6). John 
Wiley & Sons, Ltd (10.1111): 873–883. doi:10.1111/ecc.12285.
Wheeler, Heather E., Lois B. Travis, Amy Budnick, Darren Richard Feldman, Lawrence H. 
Einhorn, Robert James Hamilton, David J. Vaughn, et al. 2015. “Comprehensive 
Characterization of Cisplatin-Related Hearing Loss in U.S. and Canadian Testicular 
Cancer Survivors (TCS).” Journal of Clinical Oncology 33 (15_suppl).  American 
Society of Clinical Oncology : 9570–9570. doi:10.1200/jco.2015.33.15_suppl.9570.
Zeman, Florian, Michael Koller, Berthold Langguth, and Michael Landgrebe. 2014. “Which 
Tinnitus-Related Aspects Are Relevant for Quality of Life and Depression: Results from 
a Large International Multicentre Sample.” Health and Quality of Life Outcomes 12 (1). 
BioMed Central: 7. doi:10.1186/1477-7525-12-7.
Page 28 of 58
E-mail:editor.ija@up.ac.za  URL: http://mc.manuscriptcentral.com/tija
International Journal of Audiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
1
Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the 
impact on quality of life: a narrative systematic review.
Objective: To identify any change in quality of life (QoL) An understanding of 
the impact on quality of life (QoL) caused by chemotherapy-induced toxicities, 
such as hearing loss and tinnitus, to provide  is important to know ininformation 
in order to improve services and aid clinicians in their decision-making. 
Design: This systematic review followed the PRISMA checklist. The search 
terms were cancer, platinum-based chemotherapy, ototoxicity and “quality of 
life”QoL.. Titles and abstracts, followed by full texts, were screened by two 
independent researchers. The relevant data were extracted and quality analysis 
was performed using the NIH Quality Assessment Tool. 
Study Sample: 308 titles and abstracts were screened, and 27 full text articles 
were screened. Ten articles representing 11 studies were included in the review. 
Study design included cross- sectional studies, randomised control trials and 
longitudinal studies. 
Results: Diagnostic criteria consisted of audiograms, questionnaires, and patient 
complaints. The study quality ranged from 21.43% to 85.71%. Overall results 
found that those treated with cisplatin had more hearing loss and tinnitus than 
those treated with other therapies. Furthermore, those with hearing loss and 
tinnitus were more likely to have a lower QoL.
Conclusions: There is an urgent need to standardise diagnostics when 
investigating ototoxicity and its effect on QoL, particularly for research into risk 
factors, prevention and management. 
Keywords: cancer, platinum- based chemotherapy, survivorship, ototoxicity, 
hearing, tinnitus, quality of life
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Introduction
Cancer continues to be a life-altering diagnosis, however due to medical advances there has 
been an overall decline of 26% in cancer deaths within the past two decades (Siegel, Miller, 
and Jemal 2018). Treatment effects, howeverthough, can often cause long-term physical and 
psychological challenges for survivors (Skalleberg et al. 2017; Alfano and Rowland 2006). 
For this reason, there is a requirementa need to look into how these long-term effects impact  
quality of life (QoL) for those who are adapting to a life with and beyond cancer. 
Platinum-based chemotherapy is typically used to treat most solid tumours, including 
breast, testicular and ovarian cancers (Oun, Moussa, and Wheate 2018; Theile and Dirk 2017; 
Kelland 2007). Due to its cost effective systematic and cytotoxic effects, it has been one of 
the most efficient and widely available chemotherapies (Paken et al. 2016). However, Iit is 
widely known that platinum-based chemotherapy, although commonly used due to its 
cytotoxic effectiveness, can cause ototoxicity (Campbell and Le Prell 2018; Saladin et al. 
2015). Ototoxicity refers to any hearing deficit or tinnitus resulting from a temporary or 
permanent inner ear dysfunction, following treatment with an ototoxic drug (Paken et al. 
2016). Ototoxic drugs include aminoglycoside antibiotics such as gentamicin, loop diuretics 
such as torasemide and neurologic drugs, such as sodium valproate (Bisht and Bist 2011). 
Ototoxic effects commonly manifest as tinnitus and/or high frequency hearing loss and 
tinnitus thatwhich can later progress to lower frequencies (Waissbluth, Peleva, and Daniel 
2017). Both tinnitus and hearing lossThese are associated with a higher risk of depression, 
social isolation, anxiety (Nordvik et al. 2018) and dementia (Gurgel et al. 2014; Deal et al. 
2016)(Gurgel et al. 2014).
It may not be possible to identify the specific time point during treatment at which an 
effect first appears, making it challenging to determine the causality and risk of each therapy 
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received (Stein, Syrjala, and Andrykowski 2008). For this reason, literature reporting adverse 
health effects associated with chemotherapy can be imprecise and lacking in detail.
Furthermore, collating systematic evidence on adverse effects can be difficult. 
Specific toxicities are rarely included in key words, titles or abstracts. To overcome this 
challenge, a compromise between sensitivity and precision must be made when performing a 
systematic search (Golder and Loke 2009). 
To date, there have been no systematic reviews carried out exploring the impact on 
QoL from platinum-based chemotherapy- induced ototoxicity. 
Materials and Methods
Eligibility Criteria
The four themes which that had to be present in an article were: any mention of cancer, 
platinum-based chemotherapy, ototoxicity and quality of lifeQoL. Known key articles were 
checked in the searches to ensure all relevant articles were included in the search. There was 
no limitation on the date range of this search.
The inclusion criteria consisted of: any combination of treatments which included 
platinum-based chemotherapy for curative intent, any type of formal QoLquality of life 
assessment, any type of formal hearing loss and/or tinnitus assessment, written in the English 
language, any study design providing the relevant results were obtained after treatment and 
any cancer type other than head and neck. Any paediatric study was excluded, in addition to 
review articles, grey literature and both in vitro and in vivo studies. 
Information Sources
This systematic review was conducted following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) checklist.
Due to the nature of this systematic review and the difficulties in searching for 
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adverse effects of chemotherapy, specificity and precision were optimised in order to capture 
the most relevant articles and reduce unrelated articles. The terms used were edited 
accordingly to meet the standards of each search engine.
Search engines used were OVIDSP, NCBI, WebofScience and Cochrane. Databases 
searched therefore consisted of Medline, Pyschinfo and PyschArticles, Embase, PubMed, 
WebofScience Core Collection and the Cochrane Database. 
Study Selection 
Titles and abstracts were imported to Endnote, duplicates were removed and the remainder 
were screened by two independent authors (SP and JT) against the eligibility criteria. Any 
disagreement was resolved by consensus. Full-text articles of potentially relevant papers were 
also assessed for eligibility, once again resolving any discrepancies by consensus. 
Data Extraction Process
Determinants such as paper characteristics, type of study design, sample size, patient 
demographics, and the measurements used and analysed, in addition to the results of the 
specific study, were all extracted. The information which that could be compared across 
studies was then analysed accordingly, with the remaining information displayed as a 
description in order to capture the full results. 
Risk of Bias in Individual Studies
A quality assessment was carried out on each of the studies included in this review using a 
14-item study quality assessment tool involving pre-defined principles, the NIH’s Quality 
Assessment Tools (“Study Quality Assessment Tools | National Heart, Lung, and Blood 
Institute (NHLBI)” 2018). An item was scored 1 for matching the criteria, and scored a score 
of 0 if it was not clear or did not match the criteria. Aggregate percentages were used to 
classifyA percentage was made from the scores and classified into poor- quality (≤50%), and 
high- quality (>50%) studies. This tool was chosen based on a systematic review carried out 
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by Mols, et.al  (Mols et al. 20105). The tool was chosen as it assessed relevant aspects for 
each study type involved in this review. The- high quality and low- quality studies were 
grouped, and their results were compared to evaluate consistencies and anomalies.  
Synthesis of Results
Due to the heterogeneity of the results reported in this review, it was not possible to 
statistically combine the results. Therefore, a narrative analysis was carried out, and these 
descriptive results of each study were compared with one another. 
Outcome measures from the studies were all extracted and compared, including the 
diagnostic criteria and grading systems used. 
Risk of Bias Across Studies
The majority of the adverse effects within the studies were not clearly defined, therefore the 
risk of bias between studies was relatively high. Moreover, not all diagnostic criteria were 
specified, meaning some studies reported presence of ototoxicity but did not clarify its 
severity or symptom characteristics, i.e. whether it was hearing loss or tinnitus. The non-
randomised studies were also considered to carry a high risk of bias, as trials without blinding 
are prone to bias (Loke, Price, and Herxheimer 2007).
Results
Study Selection
A total of 645 articles were identified through the database searches performed. From this, 
337 articles were excluded due to duplications, grey literature and there being no abstracts 
available. The resulting 308 titles and abstracts were screened. The screening procedure can 
be seen inis then left 308 titles and abstracts to screen, shown in Figure 1.
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Figure 1 displaying the PRISMA flowchart methodology and results obtained for this 
systematic review.
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Study Characteristics 
The following study characteristics were extracted, as shown in Table 1: location of study, 
type of study design, population characteristics, number of participants, number of 
participants treated with platinum- based chemotherapy, diagnostic measurements for 
ototoxicity, hearing loss, tinnitus and QoLquality of life, type of platinum-based 
chemotherapy, follow-up period, if any, main objective of study and a descriptive summary 
of the study. 
 There were six6 cross-sectional studies included in this systematic review, each with 
variable timeframes since diagnosis (Bentzen et al. 2013; Bokemeyer et al. 1996; Calhoun et 
al. 1998; Miaskowski, Paul, Mastick, Schumacher, et al. 2018; Miaskowski, Paul, Mastick, 
Abrams, et al. 2018; Miaskowski, Mastick, Paul, Abrams, et al. 2018b). In total, 856 
participants were included; 565 of these received platinum-based chemotherapy. Two 
randomised control trials compared cisplatin-based regimens with other types of treatments 
and included 553 patients, with 313 of these having a platinum-based treatment (Bezjak et al. 
2008; Saad, Ghali, and Shawki 2017). Only one longitudinal study was included in this 
systematic review, following 666 patients with metastatic testicular cancer on two different 
cisplatin regimens, with 286 (52%) being followed up at 2 years (Fosså et al. 2003). Finally, 
one paper involved two separate pilot studies on low-stage testicular cancer survivors from 
Norway and the UK (Fossa and Fossg 1996). This study involved comparing opinions on 
toxicities of those treated with infradiaphragmatic radiotherapy, cisplatin, or surveillance and 
the opinions of a variety of healthcare professionals. From the 309 participants involved, 71 
of these received cisplatin (Fossa and Fossg 1996). 
Most did not report the demographics within each comparison group, but as a whole. 
For example, the Bentzen, et .al. paper describes patient characteristics as 79% women and 
21% men, with a median age of 61, and a range of 40-89 years old for survivors who 
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responded to the survey (Bentzen et al. 2013). Although the information contains those 
treated with cisplatin (n= 56), it is not possible to isolate the gender split and age range of this 
exact subgroup. 
Eight of the studies included cisplatin as the platinum-based chemotherapy, and 
three3 of the studies carried out by Miaskowskind colleagues do not specify which platinum-
based chemotherapy was used (Miaskowski, Paul, Mastick, Abrams, et al. 2018; Miaskowski, 
Mastick, Paul, Abrams, et al. 2018a; Miaskowski, Paul, Mastick, Schumacher, et al. 2018). 
Only one study investigated the difference between carboplatin and cisplatin (Saad, Ghali, 
and Shawki 2017). Moreover, only one study compared the toxicities with those treated with 
cisplatin to the normal population (Bentzen et al. 2013). 
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Table 1 displays the study characteristics extracted for this review, including the author, type 
of study, cancer type, type of platinum-based chemotherapy used, number of participants 
involved and number of participants involved treated with platinum-based chemotherapy
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Risk of Bias 
The NIH Quality Assessment Tool (“Study Quality Assessment Tools | National Heart, Lung, 
and Blood Institute (NHLBI)” 2018) were carried outwas used to assess  on each of the 
individual studies. The appraisal criteria involved answering 14 binary questions on the 
quality of the article. Table 2 displays the quality score for each assessment and the quality 
percentage calculated, with green being a good- quality study and red being a poor- quality 
study. Those with a score of >50% (n=7) were classed as a highgood- quality study, and 
those ≤50% (n=4) were classed as a poor-quality  study. The studies were grouped according 
to quality to compare any differences in results and identify any contradicting information. 
The papers with a quality score ≤50% (n=4) all compared opinions of patients and 
healthcare professionals. The papers concluded that most patients perceived the effects of  
ototoxicity as tolerable, whereas those in health professions perceived the toxicity to affect 
QoL. However, these studies were all based on hypothetical scenarios and not real life 
experiences, therefore it could be hypothesised that patients may not realise the extent to 
which how QoLquality of life can change when experiencing ototoxicity, compared to 
professionals. All but one study scoring >50% concluded that QoL is indeed affected by 
tinnitus and/or hearing loss, adding that severity correlated with the dosage and number of 
cycles. However, one high quality study carried out by Bezjack, et.al. 2008 found no 
difference in the QoL assessed across different treatments, regardless of experiencing 
ototoxicity. Yet, this study found that ototoxicity did indeed persist beyond treatment (Bezjak 
et al. 2008). There were no significant differences in results from the high quality studies 
compared to the lower quality studies. 
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Table 2 displays the study and the critical appraisal score for each study, using the NIH 
Quality Assessment Tool.
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Results of the Individual Studies
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The data extracted in 
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Table 3 demonstrates that there is no standardised outcome measurement used to assess 
ototoxicity. For example, many of the measurements used in the study analysed ototoxicity, 
yet did not specify or define ototoxicity. These studies could have measured either hearing 
loss or tinnitus. Furthermore, many studies did not consider the severity or grading of 
ototoxicity. One study did, however, perform pure tone audiometry with bone conduction 
thresholds on patients to assess the extent of their hearing loss (Bokemeyer et al. 1998). 
The studies carried out by Miaskowski assessed 8 aspects of QoL in addition to a 
questionnaire identifying the severity of hearing loss and the severity of tinnitus as separate 
items. , which was definedTinnitus was defined as “ringing or buzzing in the ears” 
(Miaskowski, Paul, Mastick, Schumacher, et al. 2018; Miaskowski, Mastick, Paul, Abrams, 
et al. 2018a; Miaskowski, Paul, Mastick, Abrams, et al. 2018). The studies compared those 
with hearing loss, tinnitus and neuropathy to those with just one of the toxicities and those 
with no toxicities. However, these studies do not report which platinum-based chemotherapy 
iwass used, the regimen used, the dosage or how many cycles each patient received. 
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Table 3 displays the results extracted from the individual studies in the systematic review. 
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Table 3 continued. 
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Discussion
Overall, the results found that those treated with platinum -based chemotherapy, specifically 
cisplatin, had significantly more hearing loss and tinnitus than the comparisoned population, 
with higher doses correlating to persisting symptoms. These results are corroborated by the 
wider This correlates with the wider literature, as it is reported thatn on average, 60-70% of 
adult patients experienced ototoxicity when treated with cisplatin (Chirtes and Albu 2016; 
Campbell and Le Prell 2018; Frisina et al. 2016; Travis et al. 2014)(Chirtes and Albu 2016; 
Campbell and Le Prell 2018). Tinnitus has also been reported in previous studies, particularly 
those with high doses of cisplatin (Campbell and Le Prell 2018). This review found that, 
those with tinnitus and hearing loss were more likely to have a lower QoL. 
It is common for there to be a reduction in QoL following the first three cycles of 
platinum-based chemotherapy in adults (Kalyanam et al. 2018). Furthermore, it is well 
documented that hearing loss negatively impacts mental wellbeing and QoL, although the use 
of hearing aids appear to improve general QoL within the first year, emphasising the 
importance of early and proper diagnosistics (Hogan et al. 2015; Fellinger et al. 2007). 
Tinnitus has also been shown to be a significant burden on QoL and has a strong 
associationrelationship with depression in the general population (Zeman et al. 2014; 
Nondahl et al. 2007). From this, it can be inferred that indeed, ototoxicity in cancer survivors 
can directly cause a reduction in QoL. However, due to the heterogeneity of the study designs 
and the lack of research carried out in this field, it cannot be categorically stated that this is 
true. 
The studies included in this review were highly variable in both their methodology 
and results. The results clearly highlight the lack of standardisation in reporting QoLquality 
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of life and ototoxicity diagnostics. Furthermore, the lack of grading means that individuals 
could be suffering from ototoxic effects and it not be reported adequately in study settings, or 
the opposite, where the reporting overestimates the ototoxic effect. Therefore, it is difficult to 
assess the strength of the results as a whole, as the nature of this field is heterogeneous. The 
lack of standardised diagnostic and grading systems is the most significant weakness in the 
reviewed studies. By pooling together similar data and carrying out a meta-analysis, powerful 
information could be identified and published, which in turn will help inform and develop 
better care and management for those experiencing ototoxicity. This research has typically 
consisted of a multitude of small-scale studies looking into different factors, making it 
difficult to compare information statistically. However, the information and data regarding 
genetic susceptibilities of ototoxicity have been statistically systematically analysed. Studies 
of high-quality and large population sizes have found that between 29-40% of testicular 
cancer patients have an ototoxic phenotype (Wheeler et al. 2015). Furthermore, a meta-
analysis of phenotypes have found a multitude of genes, including those that play a role in 
calcium homeostasis and are associated with an increased risk of ototoxicity (Tserga et al. 
2019).
Audiometry is a standardised and widely available method for quantifying hearing 
status. There are also a variety of validated tinnitus questionnaires that are used clinically for 
diagnosing and quantifying tinnitus severity readily available. Ideally, it should be clinical 
practise that in the event a patient presents with ototoxicity that these assessments be carried 
out. However, because chemotherapy is associated with many acute and life-threatening side 
effects, it is unrealistic and time-consuming to have measurement tools for each individual 
and specific side effect. However, it is of high clinical importance for the dose-limiting or 
permanent side effects to be identified and managed. For this reason, questionnaires such as 
the Scale for chemotherapy-induced long-term neurotoxicity (SCIN) which group together 
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the neurotoxic side effects, are well-used outcome measures (Oldenburg et al. 2006). These 
type of assessments, although more time-efficient, lack collecting valid information. For 
example, the questions are vague and do not allow clinicians to differentiate one toxicity 
from another, meaning the management and support offered isn’t useful. Another example of 
this is the Holistic Needs Assessment (HNA), which asks if “you have had any change in 
sight or hearing” (Wells, Semple, and Lane 2015; Biddle et al. 2016). This, although helpful 
in developing a tailored care plan, does not identify specific side effects, the severity of them 
or if it affects QoL. Furthermore, by identifying a change in hearing andd/or sight, it is 
unclear which specialist the patients should be referred to, an optician or an audiologist? 
Therefore, the is balance between not overwhelming a patient, yet also collecting reliable and 
detailed information about their side effects appears a seemingly impossible challenge. This 
has been highlighted regularly in literature, with many new proposals on which diagnostic 
criteria should be used to identify the presence and severity of ototoxicity, yet no 
standardised measures are implemented clinically at the present time (Theunissen et al. 2014; 
Chang 2011; Waissbluth, Peleva, and Daniel 2017; Crundwell, Gomersall, and Baguley 
2016; Degeest et al. 2016).
There are many potential confounding factors when assessing ototoxicity and how it 
impacts quality of life, including age at treatment, number of follow-ups and the timing of 
these follow-ups, type of treatment, dosage of treatment, type of quality of life assessment 
and the setting these were carried out in. Furthermore, the language used in the assessment 
tools can also lead to patients providing unreliable and confusing information, which does not 
always reflect their true experience. The readability of the questionnaires, therefore, is also an 
important confounding factor that should be considered when analysing this type of 
information (Atcherson et al. 2013; Gray, Zraick, and Atcherson 2019; Douglas and Kelly-
Campbell 2018). 
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The term “ototoxicity” must be defined when publishing trials and research studies. 
There needs to be a clear definition of what the authors mean, and differentiation between 
hearing loss and tinnitus informationdifferentiate between hearing loss and tinnitus 
(Waissbluth, Peleva, and Daniel 2017). Without this, a detailed analysis on the severity and 
effect on QoL remains a challenge.  
FinallyLastly, although survival rates remain the priority in cancer treatment, there 
needs to be more emphasis on the importance of permanent toxicities. As people survive 
longer and it becomes clear that there will be a life beyond cancer, QoL becomes increasingly 
important. More awareness of how long-term toxicities, such as hearing loss and tinnitus, can 
affect QoL, needs to be integrated into clinical practice. By raising awareness, the risk of 
these issues being neglected will decrease. Patients guided through the survivorship journey 
can be given relevant and tailored support, be it hearing aids, tinnitus sound therapy or 
cognitive behavioural therapy (CBT). Ototoxicity is currently neither preventable nor curable, 
therefore it is essential that a deeper understanding and increased awareness of how hearing 
loss and tinnitus affects the QoL of cancer survivors be established in order to improve long-
term symptom management.
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 Author (year) Cancer Type Platinum-based chemotherapy Number of patients total (number of 
patients receiving 
platinum based 
chemotherapy)
Time of evaluation 
following 
treatment
Patient characteristics Control Location
Bentzen 
(2013) 
Squamous cell 
carcinoma of 
anal region
Cisplatin v non-cisplatin 128 (56) ≥2 years Patients diagnosed between 2000-2007 with 
curative intent. Those treated with cisplatin 
had >200mg/m2. The median time since 
diagnosis was 66 months (range 25-112).
Age/sex matched the participants to 
the normal poulation (n=269).
Norway
Bokemeyer 
(1996)
Testicular cancer A mixture of different 
chemotherapy cocktails 
containiting cisplatin 
(P) :PVB, PEB, PEBVc, 
P(high dose)EB, PVB/PE
90 (90) Median 58 months 
(range 12-159 
months)
Cancer survivors in remission for 12 months. 
The median age of diagnosis was 28 (range 
19-53). The median follow up was 53 months 
(range 15 to 159).
Participants grouped in terms of 
treatment (PVB, PEB, PEBVc, P(high 
dose)EB, PVB/PE) and compared.
Germany
Calhoun 
(1998)
Advanced-stage 
ovarian cancer
A minimum of 6 
cisplatin cycles
15 (15) Mean 6.6 years 
(range 2.5-12 
years)
Cancer patients with a mean age of 61.3 years 
(range 44-87) who had been living with 
cancer for a mean of 6.6 years (range 2.5 to 
12 years).
Gynaecologic oncologists (n=10). USA
Various Platinum based 
chemotherapy (PBC)
623 (404) ≥3 months Cancer survivors treated with PBC  3+ months 
from their last cycle and had scale 3 or above 
on CIPN score. N= 623 (68.4% had CIPN).
Cancer survivors treatedf wih PBC, 3+ 
months since last cycle and no 
reports in CIN, hearing loss or 
tinnitus.
San Fracisco, USA
Various Platinum based 
chemotherapy (PBC)
623 (371) ≥3 months Cancer survivors treated with PBC 3+ months 
following their last cycle who reported 
Hearing loss, Tinnitus and/or CIN (n= 371).
A comparison of cancer survivors 
reporting tinnitus, hearing loss, 
hearing loss and CIN, hearing loss 
and tinnitus and CIN. 
San Fracisco, USA
Cross-
sectional 
Studies Miaskowski 
(2018)
Various Platinum based 
chemotherapy (PBC)
623 (85) ≥3 months Cancer survivors treated with PBC 3+ months 
following their last cycle who reported 
Hearing loss, Tinnitus and CIN (n= 85).
Cancer survivors without any signs of 
CIN.
San Fracisco, USA
Bezjak (2008) Earl stage NSCLC Adjuvant 
chemotherapy (4 cycles 
of cisplatin and 
vinorelbine) vs 
observation
month 0: 482 (242), 
month 36: 89 (50)
Intervals at 5, 9, 12 
weeks and at 6, 9, 
12 18, 24, 30, and 
36 months
Cancer patients, 65% male, median 61 years, 
followed up at 0 and 36 months following 
treatment.
Cancer patients treated with 
observation (n=240 at month 0, n=39 
at month 36).
Canada
RCT
Saad (2017) Stage IV NSCLC Gemcitabine and 
carboplatin vs 
gemcitabine and 
cisplatin
71 (36 cisplatin, 35 
carboplatin)
At cycle 3 and 6 of 
treatment
Patients with stage IV NSCLC excluding grade 
3+ neuropathy, 55% <55+ years and 77.5% 
male. 44 patients had multiple sites. 
Cancer patients treated with cisplatin 
compared to carboplatin. 
Egypt
Longitudinal
Fossa (2003) Metastatic 
testicular cancer
Cisplatin day 1 through 
5 at 20mg/m2. vs 
cisplatin days one 
through 3 at 50 mg/m2 
on days one and days 2. 
666 (666) Intervals at 3, 6, 12, 
and 24 months
Cancer patients, mean age 31, range 16-63, 
286 (52%) followed up after 2 years .
Comparison between cisplatin 
regimes.
Norway, The Netherlands, 
Rotterdam, UK, Belgium
Low-stage 
testicular cancer
Surveillance vs 
infradiaphragmatic 
radiotherapy vs 2-6 
cycles of cisplatin
103 (45) ≥3 months Disease-free patients who had undergone 
treatment, stage 1 seminoma.
European urologists (n=20), 
oncologists and radiotherapists 
(n=13).
Norway/UK
Pilot Study
Fossa (1996)
Low-stage 
testicular cancer
Surveillance vs 
infradiaphragmatic 
radiotherapy vs 2 cycles 
of 100mg/m2 cisplatin. 
206 (26) ≥3 months 107 cancer survivors from Noway and 99 
relapse-free patients from the UK.
Opinions from cancer survivors 
compared to opinions from Doctors 
(n=10). 
Norway/UK
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Author (year) Bentzen (2013) Bokemeyer 
(1996)
Calhoun (1998) Miaskowski (2018) Bezjak (2008) Saad 
(2017)
Fossa 
(2003)
Fossa (1996)
7/14 9/14 7/14 10/14 10/14 9/14 11/14 9/14 12/14 3/14 3/14Quality analysis 
50.00% 64.29% 50.00% 71.43% 71.43% 64.29% 78.57% 64.29% 85.71% 21.43% 21.43%
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Author Aim of study Outcome measures Results
  Tinnitus Hearing Loss Ototoxicity Quality of Life Other  
Bentzen (2013) To compare the long-
term QoL of cancer 
patients compared to 
the QoL of the normal 
population.
SCIN questionnaire: 
Have you suffered 
from ringing in your 
ears? Scored from 0-
3
SCIN questionnaire: 
Have you suffered 
from reduced 
hearing? Scored 
from 0-3
SCIN EORTC- QLQ C-30 and EORTC QLQ-
C29 questionnaire: How would you 
rate your overall quality of life during 
the past week?
Telephone 
interviews with 
pre-defined, 
structured 
questions
There were more smokers in cancer survivors than in the control population, survivors also had 
worse QoL scores overall and  in single items, the most significant being fatigue. Global QoL was 
lower in survivors. Those treated with cisplatin had siginificantly more tinnitus and non-significant 
but more hearing loss. 
Bokemeyer (1996) To evaluate the extent 
and reversibility of late 
symptoms caused by 
chemotherapy in 
testicular cancer 
survivors.
Patient complaint Pure-tone 
audiometry and 
bone conduction 
thresholds
None Wellbeing was scored from 0-10 Blood samples, 
Medical histories, 
physical 
examination, 
patient 
complaints
18 (21%) patients had persisting ototoxicity, 8 (95%) patients had transient ototoxicity and 60 
(70%) patients had no ototoxicity. There were 86 audiograms performed showing 31 (36%) 
patients with chemotherapy-induced hearing loss. However it was only possible to exclusively 
evaluate 45 of the 86 audiograms due to others having confounding hearing issues. Every patient 
which a cumulative dose of 650mg/m2 complained of persisting ototoxicity. There was a threefold 
increased risk for ototoxicity in patients with a history of noise exposure. Those with high dose of 
cisplatin had significantly worse QoL than those with lose dose, and those with persisting toxicities 
reported a worse QoL  The PEB and High CDP+ cisplatin regimens results in significantly increased 
late toxicities.
Calhoun (1998) To evaluate issues 
related to 
chemotherapy-induced 
toxicities in women and 
compare it to 
oncologists answers on 
a survey.
None None Utlity score 
with ototoxicity
Utility score comparing symptoms to 
1 (good health) and 0 (death)
None A total of 8 women had experienced at least mild ototoxicity. Patients scored ototoxicity as 0.92 
and oncologists as 0.69 in the utility questionnaire. Patients who had experienced toxicities 
assigned a higher utility score for toxicities, especially those they'd personally experienced. It was 
concluded that patients tolerated toxicities in the face of maintaining stable disease. Physicians 
were less favourable.
To compare a variety of 
QoL outcomes in cancer 
survivors with CIPN and 
no CIPN.
FACT/GOG-Ntx 
questionnaire: I have 
ringing or buzzing in 
my ears, scored from 
0-4
FACT/GOG-Ntx 
questionnaire: I 
have trouble 
hearing, scored 
from 0-4
None QoL-PV, SF-12, CES-D scale LFS fatigue 
scale, sleep disturbance GSDS, 
Attentional functional index AI, stress 
PSS and IES-R questionnaires i.e: 
During the past 4 weeks, how much of 
the time has your physical health or 
emotional problems interfered with 
your social activities (like visiting 
friends, relatives, etc.)?
None CIPN survivors statistically had a higher BMI, a higher SCQ score, a lower KPS score and were born 
prematurely. Only 613 survivors completed the hearing loss item and from these, 34.5% reported 
hearing loss (score 1+). These survivors were significantly older, had a higher SCQ score, a lower 
KPs score, more likely to be male and had a higher IES-R score. Only 609 survivors completed the 
tinnitus item, out of these, 31% reported tinnitus. Statistically, they had less education, a higher 
SCQ score, were more likely to be male, were more likely to have had platinum based 
chemotherapy and a higher IES-R score. Although the IES-R core didn't reach the cut-off for PTSD 
in this population, their scores are comparable to those with R. Arthritis. 
To identify hearing loss 
and tinnitus in survivors 
with chemotherapy-
induced neuropathy.
FACT/GOG-Ntx 
questionnaire: I have 
ringing or buzzing in 
my ears, scored from 
0-4
FACT/GOG-Ntx 
questionnaire: I 
have trouble 
hearing, scored 
from 0-4
None QoL-PV, SF-12, CES-D scale LFS fatigue 
scale, sleep disturbance GSDS, 
Attentional functional index AI, stress 
PSS and IES-R questionnaires i.e: 
During the past 4 weeks, how much of 
the time has your physical health or 
emotional problems interfered with 
your social activities (like visiting 
friends, relatives, etc.)?
None Those who had CIN/HL/TIN were statistically more likely to be male from a lower economic 
background with no childcare responsibilities. They also experienced a more severe hearing loss 
than those in the other subgroups, had a lower KPs score, more likely to have clinical depression, 
had a higher dose and more cycles of cisplatin, had a significantly increase in anxiety, experienced 
lower morning energy, lower attention function scores and lower QoL. Those with only CIN/HL 
were more likely to be older, have a higher anxiety score, but no difference in stress (IES-R or PSS 
score) and no difference in spiritual wellbeing.
Miaskowski (2018)
To identify the impact of 
CIN on symptom burden 
and QoL.
FACT/GOG-Ntx 
questionnaire: I get 
ringing or buzzing in 
my ears scored from 
0-4 
FACT/GOG-Ntx 
questionnaire: I 
have trouble 
hearing scored 
from 0-4
None QoL-PV, SF-12, CES-D scale LFS fatigue 
scale, sleep disturbance GSDS, 
Attentional functional index AI, stress 
PSS and IES-R questionnaires: During 
the past 4 weeks, how much of the 
time has your physical health or 
emotional problems interfered with 
your social activities (like visiting 
friends, relatives, etc.)?
None From the 609 survivors, 68.9%  had CIN and 31.4% did not have CIN. Those with all HL/TIN/CIN 
were significantly older, more likely to be unemployed, had a lower annual household income with 
no child care responsibilities, a higher BMI, a higher number of comorbidities, a lower KPS score, 
had received fewer cancer treatments, had more back pain, were more likely to have clinical 
depression and kidney disease and didn't exercise. This population also had a significantly lower 
QoL with every specific item addressed on the questionnaire other than spiritual wellbeing. 
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Bezjak (2008) To identify the QoL 
outcome in an analysis 
of a RCT.
None 15 items from NCIC 
CTG questionnaire: 
loss of hearing 
scored from 0-4
None EORTC QLQ-C30 questionnaire: How 
would you rate your overall quality of 
life during the past week? 
None Those treated with chemotherapy had significantly worse fatigue, lower appetite, hair loss and 
vomiting which all subsided. There was no difference in QoL overall, but statistically significant 
worse hearing loss in chemotherapy group (p=0.03) which was deemed permanent at 12 months. 
A higher QoL correlated with longer survival, and the only persistent symptoms reported in this 
study were neurotoxicity and ototoxicity in the chemotherapy group. 
Saad (2017) To compare the two 
treatment regimens in 
terms of toxicities and 
QoL. 
None None NCI-CTCAE 
grading system, 
however is not 
clear
FACT-L and TOI questionnaires: I am 
content with the quality of my life 
right now  scored from 0-4
None Rates of ototoxicity were significant higher in Gem/Cis group. Ototoxicity was reported in 9 
patients (25%) in the cisplatin group at Grade 1, and no ototoxicity was reported in the carbplatin 
group. 
Fossa (2003) To describe QoL in 
metastatic testicular 
cancer patients treated 
with cisplatin.
None None TC Module EORTC QLQ-C30 questionnaire: How 
would you rate your overall quality of 
life during the past week? 
None A total of 42 (6%) patients stopped chemotherapy due to ototoxicity. Tinnitus was higher in those 
treated with the 4 cycles and 3 day regimen at all time points and overall. A mean of 4.9 had 
tinnitus at baseline, with 5% improving, 69% who had no change and 26% worsened. A mean of 3.1 
had hearing loss at baseline, with 3% improving, 76% experienced no change and 21% had 
worsening of symptoms. At 6 months the group receiving the 4 cycles and 3 day regimen had 
worse hearing loss. Long term ototoxicity was reported by 20-25% of patients. Tinnitus occured in 
50% of patients and hearing loss for speech frequencies in 10% and for high frequency in 60% of 
patients. 
To identify long-term 
somatic and 
pyscological morbidity 
in patients and compare 
this with opinions from 
doctors on QoL.
None Non-validated 
qustionnaire with 
15 items. 
Ototoxicity: 
impaired hearing
Non-validated 
qustionnaire 
with 15 items. 
Ototoxicity: 
impaired 
hearing
Non-validated qustionnaire with 15 
items including QoL issues
Rank significance 
of indicated 
physical and 
psychosocial 
dimension in 
hypothetical 
scenarios 
The overall satisfaction with the health-care provision was reported as the most relevant QoL item 
from the patients point of view, however this was not recognised by the doctors. Ototoxicity was 
scored by patients as 2.7 (SD 2.1) and by the doctors, 4.7 (SD 1.6) (of a score from 1 to 7).
Fossa (1996)
To dentify long-term 
somatic and 
pyscological morbidity 
in patients and compare 
this with opinions from 
doctors on QoL.
None None Non-validated 
questionnaire 
with 18 items. 
have you 
suffered from 
reduced 
hearing/ringing 
in the ears?
Non-validated qustionnaire with 18 
items including QoL issues
None Reduced hearing and tinnitus was scored 1.3 (SD 0.72) by the patients and 1.4 (SD 0.66) by the 
doctors on a scale of 1 to 7. 
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Records excluded (n = 337)
Duplicates (n = 271)
Grey Literature (n = 8)
No abstract (n = 58)
Titles and abstracts 
screened
(n = 308)
Records excluded (n = 281)
Duplicates (n = 56)
No full text (n = 3) 
In vivo studies (n = 9)
In vitro studies (n = 10) 
Paediatric studies (n = 73)
Grey literature (n = 8)
Not relevant (n = 73)
Review article (n = 49)
Full-text articles assessed 
for eligibility
(n = 27)
Full-text articles excluded
(n = 17)
Not English language (n = 1)
Not relevant to study (n = 6)
Review (n = 2)
Paediatric studies (n = 1)
Grey Literature (n = 6)
Palliative care (n = 1)
Studies included in 
qualitative synthesis
(n = 10)
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